Last reviewed · How we verify

GP2015 — Competitive Intelligence Brief

GP2015 (GP2015) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: G-CSF receptor agonist (biosimilar). Area: Oncology.

phase 3 G-CSF receptor agonist (biosimilar) G-CSF receptor (GCSFR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

GP2015 (GP2015) — Sandoz. GP2015 is a biosimilar of pegfilgrastim that stimulates neutrophil production by binding to G-CSF receptors on bone marrow progenitor cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GP2015 TARGET GP2015 Sandoz phase 3 G-CSF receptor agonist (biosimilar) G-CSF receptor (GCSFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (G-CSF receptor agonist (biosimilar) class)

  1. Sandoz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GP2015 — Competitive Intelligence Brief. https://druglandscape.com/ci/gp2015. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: